2026 03 27 12 00 00 3263711
Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU appr...
Publisher
France
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU appr...
Source route
Continue on sanofi.com
Leave the platform to read the original full article on the publisher site.
Source: Sanofi News
Scope: Industry
Related coverage
More related coverage
Press releaseMar 27, 2026Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated…
- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven...
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic ob...
20260327 Whc Reg
Gedeon Richter Investors Announcements Richter receives European Commission approval for FYLREVY® (E...
Mar.26.2026R & DOno Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan
Application submitted for manufacturing and marketing approval of ripretinib in Japan for the indica...